USPTO serial 78178624
P
Reviewed by CopyMark Law Group
Reg. 3212165Status 710
- Filing date
- Status date
- Registration date
- Feb 27, 2007
- Examiner
- CHOSID, ROBIN S
- Law office
- POST REGISTRATION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with P?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Pamela S. Ratliff
JERRY W MILLS BAKER BOTTS LLP2001 ROSS AVE STE 600DALLAS, TX 75201-2900UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in the manufacture of pharmaceuticals, cosmetics, and healthcare products; chemicals for use in science, namely, reagents for scientific research; chemicals for use in biotechnology and chemicals produced through biotechnological processes, namely, therapeutic proteins and biologics for scientific use in drug discovery; peptide sand polypeptide and small molecules for use in scientific research; all of the aforesaid for use in assays, screens and diagnosis | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical preparations for therapeutic, prophylactic and or pharmacological purposes, namely, for use in relation to abdominal disease, abnormal substrate concentration, asthenia, atrophy, breast disease, cardiovascular disease, degeneration, dermatological disease, dystrophy, ear, nose, throat disease, endocrine disease, fatigue, gastro-intestinal disorder, genetic disorder, genitourinary disease, growth disorder, hematological disease, immune disorder, immunomodulation, infection, inflammation, injury, metabolic disorder, mouth disease, movement disorder, musculoskeletal disease, neoplasm, neurological, mental and cognitive disorder, nutritional disorder, ocular disease, pain, pregnancy disorder, prophylaxis, renal disease, respiratory disease, sleep disorder, somatosensory disorder, temperature disorder, toxicity and intoxication, ulcer,uterine motility; pharmaceutical preparations comprised of peptides and polypeptides for use in relation to abdominal disease, abnormal substrate concentration, asthenia, atrophy, breast disease, cardiovascular disease, degeneration, dermatological disease, dystrophy,ear, nose, throat disease, endocrine disease, fatigue, gastro-intestinal disorder, genetic disorder, genitourinary disease, growth disorder, hematological disease, immune disorder, immunomodulation, infection, inflammation, injury, metabolic disorder, mouth disease, movement disorder, musculoskeletal disease, neoplasm, neurological, mental and cognitive disorder, nutritional disorder, ocular disease, pain, pregnancy disorder, prophylaxis, renal disease, respiratory disease, sleep disorder, somatosensory disorder, temperature disorder, toxicity and intoxication, ulcer, uterine motility; chemicals for use in biotechnology and chemicals produced through biotechnological processes, namely, vaccines | SECTION 8 - CANCELLED | — |
| 009 | Computer hardware; data processors; computer software for use in the design or identification and characterization of genes and proteins through bioinformatics and related techniques; computer software for the design and identification of chemical entities for drug discovery research; computer software for use in gene therapy and disease diagnosis; computer software comprised of algorithms for use in analysis and data-mining of sequence chemical databases | SECTION 8 - CANCELLED | — |
| 042 | Providing temporary use of online non-downloadable computer software for use in the design or identification and characterization of genes and proteins through bioinformatics related techniques; providing temporary use of online non-downloadable software for the design or identification of chemical entities for drug discovery research; providing temporary use of online non-downloadable computer software for use in gene therapy and disease diagnosis; providing temporary use of online non-downloadable computer software comprised of algorithms for use in analysis and data-mining of sequence and chemical databases; providing databases and online databases featuring complementary peptide sequences to all known genes in the human, bacterial, viral, animal and plant genomes; proteomic, genomic, bioinformatics, chemical and scientific consultation services, namely, providing advice and consultation in the fields of genomics, informatics, study of protein properties molecular design; medical, scientific and biotechnological research, namely, identification and characterization of genes and proteins and the design or identification of chemical entities through bioinformatics and related techniques, and providing consultancy and advisory services relating thereto; consultancy, advice and provision of information relating to drug discovery research, disease diagnosis; design, creation and provision of databases, namely, databases for the identification and characterization of genes, proteins and small molecules; design and creation of computer software for data-mining; design, creation and development of proprietary informatics technology, namely for the location and definition of peptide and small molecule ligands; use of bioinformatics and related techniques to design the core regions of molecular functionality and to enable the generation, design, development and validation of peptide and small molecule ligands for existing and novel targets; prediction and design of peptides from DNA sequence data; data-mining operations; scientific research, namely, identification of targets for therapeutic applications and design of chemical inhibitors, agonists and antagonists; design, optimization and development of chemical inhibitors, agonists and antagonists for specific targets for therapeutic applications; design, creation and provision of informatics based programs designed to monitor and research scientific databases and identify potential leads matched to accompany discovery portfolio; genetic research services, namely, obtaining and analyzing genetic or chemical information; gene sequencing; laboratory research and collaboration with academic research groups in the field of drug discovery and healthcare research; pharmaceutical and bio technical research, namely, collaboration with pharmaceutical and biotechnology companies; drug discovery and development programs; synthesis of peptides and small molecules | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Proteom Limited
- Other trademarks owned by Proteom Limited
- Other trademarks owned by Proteom Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named P
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 4, 2013 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 29, 2009 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jan 6, 2009 | PLGL | ASSIGNED TO PARALEGAL | — |
| Nov 20, 2008 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Feb 27, 2007 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 11, 2007 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Dec 18, 2006 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Dec 18, 2006 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Jun 21, 2006 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Jun 20, 2006 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 20, 2006 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 20, 2006 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 20, 2006 | FAXX | FAX RECEIVED | — |
| Dec 20, 2005 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 27, 2005 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Sep 27, 2005 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 7, 2005 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 30, 2005 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 20, 2005 | ALIE | ASSIGNED TO LIE | — |
| Jun 15, 2005 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 14, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| May 26, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 26, 2005 | PAPER RECEIVED | — | |
| Nov 22, 2004 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 22, 2004 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 28, 2004 | FAXX | FAX RECEIVED | — |
| May 28, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 1, 2004 | GAUD | NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED | — |
| Oct 30, 2003 | CFIT | CASE FILE IN TICRS | — |
| Sep 29, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 29, 2003 | PAPER RECEIVED | — | |
| Mar 25, 2003 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 24, 2003 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 31, 2002 | PAPER RECEIVED | — |